AUTHORS
Jessica Allen, MD, Geoffrey Shouse, DO PhD2, Yun Choi, MD3, Jess Hatfield, MD4, Cassandra Duarte, MD5, Zain El-amir, MD6, Ly V Do, MD7, Kanithra Sekaran, MD8, Keshav Raghavendran9, Megan Melody, MD, MS10, Taylor Kujawa, PharmD11, Yasmin H Karimi, MD12, Priyanka A. Pophali, MD13, Reem Karmali, MD14, Joanna M Rhodes, MD, MSCE15, Mengyang Di, MD, PhD16, Praveen Ramakrishnan Geethakumari, MD, MS, MBA, FACP17, John L Vaughn, MD, MS18, Yazeed Sawalha, MD19, Natalie S Grover, MD20, Adam J. Olszewski, MD21, Narendranath Epperla, MD, MS, FACP22
AFFILIATIONS
1 Huntsman Cancer Institute, Salt Lake City, Utah, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 Ohio State University, Columbus, Ohio, United States
4 Unc Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
5 University of Colorado Hospital, Aurora, Colorado, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Wisconsin-Madison, Madison, Wisconsin, United States
8 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
9 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
10 Tgh Cancer Institute, Tampa, Florida, United States
11 Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 University of Michigan, Ann Arbor, Michigan, United States
13 University of Wisconsin-Madison, Madison, Wisconsin, United States
14 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
15 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
16 Fred Hutch Cancer Center, Seattle, Washington, United States
17 UT Southwestern, Dallas, Texas, United States
18 NYU Langone Hospital Long Island, Mineola, New York, United States
19 Ohio State University, Columbus, Ohio, United States
20 Unc Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
21 Brown University, Providence, Rhode Island, United States
22 Huntsman Cancer Institute, Salt Lake City, Utah, United States
ABSTRACT
Introduction
The treatment (tx) landscape for MZL expanded with the introduction of targeted and immunomodulatory agents including lenalidomide (len). In the MZL subgroup of the AUGMENT trial, len+rituximab (R2) achieved an overall response rate (ORR) of 69% and a complete response rate (CRR) of 29%, though no significant differences in progression-free survival (PFS) or overall survival (OS) were observed compared with R+placebo. Grade ≥3 adverse events occurred in 69% of patients (pts) receiving R2, most commonly cytopenias. However, real-world data evaluating the effectiveness and tolerability of len-based therapy in MZL remain limited. We therefore evaluated the real-world effectiveness and tolerability of len +/- anti-CD20 monoclonal antibody in pts with MZL.
Methods
This is a multicenter (14 US sites) retrospective study of adults with MZL diagnosed between 2010 and 2024 who received novel agents including len, BTK inhibitors, and cellular therapies in any line of therapy (LOT). Baseline characteristics were summarized descriptively. Endpoints included ORR, CRR, PFS, and OS.
Response rates were assessed using the Lugano Criteria. ORR and CRR were compared by LOT using Fisher's exact test and reported 95% CI; these analyses were considered descriptive because of small sample size. PFS and OS were estimated using the Kaplan–Meier method, with descriptive subgroup comparisons performed using the log-rank test and proportional hazards models.
Results
Among the 207 pts with MZL who received novel agents, 49 were treated with len-based therapy. Most pts (46/49, 94%) received R2 (n=38, 78%) or len + obinutuzumab (n=8, 16%), while 3 (6%) received len monotherapy. The median age at len initiation was 70 years (range 43-90) and 34 (69%) were male. MZL subtypes included extranodal (EMZL, n=18; 37%), nodal (NMZL, n=18; 37%), splenic (SMZL, n=9; 18%), and MZL not otherwise specified (MZL-NOS, n=4; 8%). Forty pts (83%) had ECOG PS of 0-1 and 41 (87%) had stage III/IV disease. Ten pts (21%) had refractory disease following 1L therapy. Among pts with available data, elevated LDH was present in 12/35 (34%), Ki-67 ≥20% in 14/30 (47%), complex karyotype in 8/26 (31%), and TP53 mutation in 3/18 (17%).
In the 1L, 24 pts (49%) received R monotherapy and 18 (37%) received chemoimmunotherapy, most commonly R-bendamustine (n=12). The median number of prior LOT before len-based tx was 2. Len-based therapy was administered in 1L in 3 pts (6%), 2L in 12 (25%), 3L in 9 (19%), 4L in 11 (23%), and 5L or later in 14 (29%).
Among 45 response evaluable pts, the ORR was 64% (95% CI, 49?78) and the CRR was 42% (95%CI, 28?58). ORR and CRR did not differ significantly by LOT or MZL subtype. However, pts with SMZL had a numerically higher CRR (50%) than those with EMZL (38%), NMZL (44%), and MZL-NOS (33%).
At a median follow-up of 49 months, the median PFS was 28.6 months (95%CI 14.5-not reached), and median OS was not reached. The estimated 24-month PFS and OS were 52% (95%CI 38.8-68.8) and 76% (95%CI 64.1-89.5). There were no differences in PFS rates by LOT (p=0.53) or by MZL subtype (p=0.94).
We then compared the outcomes of pts receiving len-based therapy and zanubrutinib (n=109 in our real-world cohort). The 24-month PFS rates were 52% for len-based therapy vs. 68% for zanubrutinib. In a model stratified by LOT, len-based therapy was not associated with a significantly different risk of progression or death compared with zanubrutinib (HR=1.41, 95%CI, 0.87–2.27, p=0.16).
Seventeen (35%) pts discontinued len due to tx related toxicity, and 25 (51%) required dose reductions. The most common toxicities leading to dose reduction or discontinuation were cytopenias, rash, and fatigue. Five (10%) developed a secondary malignancy after tx with len. Eight pts (16%) died while receiving len or within 6 months of disease progression before initiating another LOT; of these, 2 (4%) died from infection.
Discussion
In this multicenter real-world study, len-based tx demonstrated durable clinical activity across MZL subtypes and LOT, supporting its role as an effective tx option in routine practice. PFS was comparable to that observed with zanubrutinib in our cohort. However, the high rates of tx discontinuation and dose reduction due to toxicity underscore the importance of careful toxicity management. Prospective comparative studies are needed to better define the relative efficacy and tolerability of len-based vs emerging therapeutic approaches in MZL.
DISCLOSURES
Jessica Allen, MD: No relevant conflicts of interest to declare.